Santhera News, Researches and Articles

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Latest Articles

Support World Duchenne Awareness Day 2025 with DMDWarrior

Editorials August 30, 2025 1

World Duchenne Awareness Day will be observed globally on...

Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE (Vamorolone) in India

Press Releases August 29, 2025 2

Santhera Pharmaceuticals announces the signing of an exclusive agreement...

ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy

Press Releases August 25, 2025 0

ITF Therapeutics affiliate of Italfarmaco, today announced publication of...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Treatments December 26, 2024 5

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Research January 5, 2025 7

The results of new gene therapy studies for Duchenne...

Duchenne Muscular Dystrophy: Treatment & Cost

Editorials January 2, 2025 1

The excitement you feel until your child is born...

Santhera

Must Read

Accredited Duchenne Centers (ADC) Aims to Provide Uniform and Up-to-date Care for All People Living with Duchenne Muscular Dystrophy

RGX-202 Gene Therapy Phase 3 Clinical Trial Begins

Entrada Therapeutics Begins Clinical Trials in Europe for Exon 44 and Exon 45 Skipping Therapies